
Upgrades
According to Morgan Stanley, the prior rating for Royalty Pharma PLC (NASDAQ:RPRX) was changed from Equal-Weight to Overweight. In the fourth quarter, Royalty Pharma showed an EPS of $0.80, compared to $0.27 from the year-ago quarter. The current stock performance of Royalty Pharma shows a 52-week-high of $47.10 and a 52-week-low of $34.86. Moreover, at the end of the last trading period, the closing price was at $39.84.